Difference between revisions of "Elotuzumab (Empliciti)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Monoclonal antibody that binds to CS1, a cell surface protein that is overly expressed on myeloma cells compared to normal cells.<ref>[http://www.themmrf.org/living-with-multiple-myeloma/newly-diagnosed-patients/what-is-multiple-myeloma/elotuzumab-huluc63.html Elotuzumab (HuLuc63) @ the Multiple Myeloma Research Foundation]</ref> | Class/mechanism: Monoclonal antibody that binds to CS1, a cell surface protein that is overly expressed on myeloma cells compared to normal cells.<ref>[http://www.themmrf.org/living-with-multiple-myeloma/newly-diagnosed-patients/what-is-multiple-myeloma/elotuzumab-huluc63.html Elotuzumab (HuLuc63) @ the Multiple Myeloma Research Foundation]</ref> | ||
| Line 14: | Line 12: | ||
No information available. | No information available. | ||
| + | ==History of changes in FDA indication== | ||
| + | * 5/19/2014: Granted FDA breakthrough designation "for use in combination with [[Lenalidomide (Revlimid) | lenalidomide]] and [[Dexamethasone (Decadron) | dexamethasone]] for the treatment of [[Multiple myeloma | multiple myeloma]] in patients who have received one or more prior therapies." | ||
| + | |||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Antibody medications]] | ||
| + | |||
| + | [[Category:Multiple myeloma medications]] | ||
| + | |||
| + | [[Category:Investigational]] | ||
Revision as of 16:21, 12 November 2014
General information
Class/mechanism: Monoclonal antibody that binds to CS1, a cell surface protein that is overly expressed on myeloma cells compared to normal cells.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Diseases for which it is used
Patient drug information
No information available.
History of changes in FDA indication
- 5/19/2014: Granted FDA breakthrough designation "for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies."